Silvio Danese

List of Publications by Year in Descending Order

595 papers	27,004 citations	77 h-index	149 g-index
748 ext. papers	35,054 ext. citations	6.6 avg, IF	7.5 L-index

#	Paper	IF	Citations
595	P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study. *Journal of Crohn's and Colitis*, **2022**, 16, i379-i380	1.5	1
594	OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 study. *Journal of Crohn's and Colitis*, **2022**, 16, i026-i027	1.5	2
593	P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials. *Journal of Crohn's and Colitis*, **2022**, 16, i460-i460	1.5	1
592	DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. *Journal of Crohn's and Colitis*, **2022**, 16, i132-i134	1.5	
591	The prophylactic use of endoscopic vacuum therapy for anastomotic dehiscence after rectal anterior resection: is it feasible for redo surgery?. *Techniques in Coloproctology*, **2022**, 26, 319	2.9	4
590	OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial. *Journal of Crohn's and Colitis*, **2022**, 16, i007-i008	1.5	0
589	DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2022**, 16, i090-i091	1.5	2
588	Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.. *Journal of Crohn's and Colitis*, **2022**, 16, ii30-ii41	1.5	3
587	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.. *Advances in Therapy*, **2022**, 1	4.1	1
586	OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial. *Journal of Crohn's and Colitis*, **2022**, 16, i004-i005	1.5	2
585	Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease.. *Clinics in Colon and Rectal Surgery*, **2022**, 35, 72-77	2.3	
584	P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn's Disease and Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2022**, 16, i434-i435	1.5	
583	DOP80 Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition in Ulcerative Colitis (UC) (Phase 2b Vibrato study). *Journal of Crohn's and Colitis*, **2022**, 16, i124-i124	1.5	0
582	DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies. *Journal of Crohn's and Colitis*, **2022**, 16, i085-i087	1.5	0
581	P267 Milan Ultrasound Criteria are accurate in assessing endoscopic remission and treatment response in patients with ulcerative colitis. *Journal of Crohn's and Colitis*, **2022**, 16, i306-i307	1.5	
580	P230 Ultrasonography-based and Magnetic Resonance-based L'hann Index: two sides of the same coin. *Journal of Crohn's and Colitis*, **2022**, 16, i278-i279	1.5	1
579	OP19 Classifying perianal fistulising Crohn's Disease: An expert-consensus to guide decision-making in daily practice and clinical trials. *Journal of Crohn's and Colitis*, **2022**, 16, i021-i022	1.5	0

578	OP15 A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2022**, 16, i015-i017	1.5	1
577	Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results.. *Gastroenterology*, **2022**,	13.3	3
576	Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study.. *Gastroenterology*, **2022**,	13.3	12
575	Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1 stabiliser, for treatment of ulcerative colitis.. *Alimentary Pharmacology and Therapeutics*, **2022**, 55, 401	6.1	0
574	JAK inhibitors in crohn's disease: ready to go?. *Expert Opinion on Investigational Drugs*, **2022**, 1-17	5.9	
573	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.. *Gastroenterology*, **2022**,	13.3	2
572	Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn Disease. *GastroHep*, **2022**, 2022, 1-12	1	
571	Endoscopic vacuum therapy for post-esophagectomy anastomotic dehiscence as rescue treatment: a single center case series.. *Esophagus*, **2022**, 1	5.4	3
570	Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.. *The Lancet Gastroenterology and Hepatology*, **2022**, 7, 390-391	18.8	1
569	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis.. *Journal of Multidisciplinary Healthcare*, **2022**, 15, 815-824	2.8	0
568	Is it time to include older adults in inflammatory bowel disease trials? A call for action. *The Lancet Healthy Longevity*, **2022**, 3, e356-e366	9.5	1
567	Composite outcomes in observational studies of Crohn disease: a systematic review and meta-analysis. *Therapeutic Advances in Gastroenterology*, **2022**, 15, 175628482210927	4.7	
566	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 265-272	6.1	3
565	Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review. *United European Gastroenterology Journal*, **2021**, 9, 1157	5.3	1
564	Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement. *BMC Psychology*, **2021**, 9, 186	2.8	0
563	Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2021**,	18.8	12
562	Magnetic Resonance Elastography for Assessing Fibrosis in Patients with Crohn's Disease: A Pilot Study. *Digestive Diseases and Sciences*, **2021**, 1	4	1
561	The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review. *Cancers*, **2021**, 13,	6.6	6

560	Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
559	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. *The Lancet Gastroenterology and Hepatology*, **2021**,	18.8	7
558	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. *Alimentary Pharmacology and Therapeutics*, **2021**,	6.1	5
557	Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211059954	4.7	3
556	'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. *Current Drug Targets*, **2021**, 22, 117-125	3	2
555	Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2021**,	6.1	2
554	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. *Drugs*, **2021**, 81, 1859-1879	11.1	3
553	Thrombosis in IBD in the Era of JAK Inhibition. *Current Drug Targets*, **2021**, 22, 126-136	3	1
552	Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. *Virchows Archiv Fur Pathologische Anatomie*	5.1	8
551	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 2567-2576.e9	6.9	2
550	Ethnic Differences in the Smoking-related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. *Journal of Crohn's and Colitis*, **2021**, 15, 1658-1678	1.5	0
549	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. *Current Drug Targets*, **2021**, 22, 370-378	3	
548	Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. *Drug Safety*, **2021**, 44, 645-660	5.1	4
547	Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn's Disease. *Journal of Crohn's and Colitis*, **2021**, 15, 1621-1630	1.5	4
546	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	2
545	Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2021**, 15, 1631-1640	1.5	2
544	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. *Gastroenterology*, **2021**, 160, 1570-1583	13.3	191
543	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. *United European Gastroenterology Journal*, **2021**, 9, 451-460	5.3	6

542	P383 Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study. *Journal of Crohn's and Colitis*, **2021**, 15, S395-S396	1.5	0
541	Reply. *Gastroenterology*, **2021**, 160, 2223-2224	13.3	
540	DOP84 Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn's Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study. *Journal of Crohn's and Colitis*, **2021**, 15, S115-S116	1.5	
539	Reply. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	
538	P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study. *Journal of Crohn's and Colitis*, **2021**, 15, S305-S305	1.5	
537	Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. *Digestive and Liver Disease*, **2021**, 53, 691-696	3.3	2
536	Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. *Inflammatory Bowel Diseases*, **2021**, 27, 2023-2030	4.5	8
535	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. *Gastroenterology*, **2021**, 160, 2435-2450.e34	13.3	45
534	Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 2324-2332.e6	6.9	4
533	IBD goes home: from telemedicine to self-administered advanced therapies. *Expert Opinion on Biological Therapy*, **2021**, 1-13	5.4	0
532	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. *Lancet, The*, **2021**, 397, 2372-2384	40	36
531	Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. *Autoimmunity Reviews*, **2021**, 20, 102832	13.6	8
530	Defining difficult-to-treat inflammatory bowel disease: why and how. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 520-522	18.8	2
529	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. *Autoimmunity Reviews*, **2021**, 20, 102849	13.6	3
528	A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. *Journal of Crohn's and Colitis*, **2021**, 15, 152-161	1.5	10
527	Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic. *Gastroenterology*, **2021**, 160, 472-473	13.3	2
526	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. *Inflammatory Bowel Diseases*, **2021**, 27, 106-122	4.5	6
525	Point-of-Care Ultrasound in Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2021**, 15, 143-151	1.5	6

524	Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. *BioDrugs*, **2021**, 35, 35-45	7.9	0
523	Medical therapy versus surgery in moderate-to-severe ulcerative colitis. *Digestive and Liver Disease*, **2021**, 53, 403-408	3.3	3
522	Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. *Expert Opinion on Biological Therapy*, **2021**, 21, 37-46	5.4	3
521	Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?. *Expert Opinion on Biological Therapy*, **2021**, 21, 47-55	5.4	3
520	Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. *Journal of Crohn's and Colitis*, **2021**, 15, 551-566	1.5	1
519	TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. *Journal of Crohn's and Colitis*, **2021**, 15, 840-859	1.5	11
518	Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis. *Inflammatory Intestinal Diseases*, **2021**, 6, 123-131	2.5	5
517	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. *MAbs*, **2021**, 13, 1868078	6.6	6
516	The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases. *Journal of Clinical Medicine*, **2021**, 10,	5.1	5
515	Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. *Journal of Crohn's and Colitis*, **2021**, 15, 938-949	1.5	8
514	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. *World Journal of Gastroenterology*, **2021**, 27, 4276-4297	5.6	2
513	Challenges and Opportunities in IBD Clinical Trial Design. *Gastroenterology*, **2021**, 161, 400-404	13.3	1
512	Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 659-667	18.8	6
511	The Inflammatory Bowel Disease Transcriptome and Metatranscriptome Meta-Analysis (IBD TaMMA) framework. *Nature Computational Science*, **2021**, 1, 511-515		5
510	Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. *Journal of Crohn's and Colitis*, **2021**,	1.5	8
509	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 857-873	24.2	5
508	PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. *Gastroenterology*, **2021**, 161, 1853-1864.e10	13.3	3
507	An Unusual Case of Cardiac Involvement in Crohn's Disease. *Gastroenterology*, **2021**, 161, 431-433	13.3	0

506	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. *New England Journal of Medicine*, **2021**, 385, 1280-1291	59.2	35
505	Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	7
504	Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1899-1905.e1	6.9	3
503	Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents. *Expert Opinion on Investigational Drugs*, **2021**, 30, 1037-1046	5.9	1
502	Adalimumab biosimilar in inflammatory bowel disease. *The Lancet Gastroenterology and Hepatology* , **2021**, 6, 775-776	18.8	
501	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). *Gastroenterology*, **2021**, 161, 1156-1167.e3	13.3	2
500	Gut eukaryotic virome in colorectal carcinogenesis: Is that a trigger?. *Computational and Structural Biotechnology Journal*, **2021**, 19, 16-28	6.8	7
499	SARS-CoV-2 vaccination in IBD: more pros than cons. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 211-213	24.2	16
498	Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. *Therapeutic Advances in Gastroenterology*, **2021**, 14, 17562848211005692	4.7	1
497	Going Beyond Bacteria: Uncovering the Role of Archaeome and Mycobiome in Inflammatory Bowel Disease.. *Frontiers in Physiology*, **2021**, 12, 783295	4.6	1
496	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 265-272	6.1	7
495	Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 712-721	6.1	0
494	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. *Journal of Clinical Medicine*, **2020**, 9,	5.1	17
493	Author response to: Covid-19-related pancreatic injury. *British Journal of Surgery*, **2020**, 107, e191	5.3	1
492	Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2134-2135	6.9	71
491	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 997-998	6.1	1
490	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. *Gut*, **2020**, 69, 1213-1217	19.2	208
489	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 1209-1210	6.1	

488	The day after COVID-19 in IBD: how to go back to 'normal'. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 441-443	24.2	12
487	The trend of C-Reactive protein allows a safe early discharge after surgery for Crohn's disease. *Updates in Surgery*, **2020**, 72, 985-989	2.9	3
486	Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 631-632	18.8	43
485	Liver tests abnormalities in COVID-19: trick or treat?. *Journal of Hepatology*, **2020**, 73, 1275-1276	13.4	30
484	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 507-516	24.2	13
483	Targeting the gut layers in Crohn's disease: mucosal or transmural healing?. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 775-787	4.2	4
482	JAK selectivity: more precision less troubles. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 789-796	4.2	2
481	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 797-806	4.2	2
480	Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity?. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
479	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. *Journal of Crohn's and Colitis*, **2020**, 14, 1503-1511	1.5	34
478	Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 819-828	4.2	1
477	Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. *Journal of Crohn's and Colitis*, **2020**, 14, S815-S819	1.5	4
476	Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease. *Techniques in Coloproctology*, **2020**, 24, 421-448	2.9	23
475	Challenges and opportunities for IBD drug development: from early stage to regulatory approval. *Gut*, **2020**, 69, 1157-1161	19.2	3
474	Emerging therapies for the treatment of ulcerative colitis. *Expert Opinion on Emerging Drugs*, **2020**, 1-9	3.7	5
473	Statins and inflammatory bowel disease: Where do we stand?. *European Journal of Internal Medicine* , **2020**, 75, 10-14	3.9	4
472	Colonic diverticular disease. *Nature Reviews Disease Primers*, **2020**, 6, 20	51.1	40
471	Management of IBD during the COVID-19 outbreak: resetting clinical priorities. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 253-255	24.2	76

470	Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. *Journal of Crohn's and Colitis*, **2020**, 14, 1330-1333	1.5	55
469	DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension. *Journal of Crohn's and Colitis*, **2020**, 14, S049-S049	1.5	1
468	P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension. *Journal of Crohn's and Colitis*, **2020**, 14, S403-S403	1.5	1
467	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. *Gastroenterology*, **2020**, 159, 139-147	13.3	54
466	Crohn's disease. *Nature Reviews Disease Primers*, **2020**, 6, 22	51.1	131
465	Impact of therapies on bowel damage in Crohn's disease. *United European Gastroenterology Journal*, **2020**, 8, 410-417	5.3	7
464	Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 820-830	6.1	17
463	Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. *Techniques in Coloproctology*, **2020**, 24, 397-419	2.9	16
462	Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. *Pharmacological Research*, **2020**, 160, 105061	10.2	6
461	Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
460	JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2020**, 14, 1185-1187	1.5	2
459	Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. *The Lancet Gastroenterology and Hepatology* , **2020**, 5, 819-828	18.8	42
458	Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. *Expert Opinion on Biological Therapy*, **2020**, 20, 421-427	5.4	6
457	Modulation of sphingosine-1-phosphate in ulcerative colitis. *Expert Opinion on Biological Therapy*, **2020**, 20, 413-420	5.4	9
456	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. *Inflammatory Bowel Diseases*, **2020**, 26, 1562-1571	4.5	12
455	DOP13 Clinical and endoscopic response to ustekinumab in Crohn's disease: Week 16 interim analysis of the STARDUST trial. *Journal of Crohn's and Colitis*, **2020**, 14, S049-S052	1.5	4
454	Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2020**, 14, 1066-1073	1.5	7
453	Reply. *Gastroenterology*, **2020**, 158, 1177-1178	13.3	

452	Review article: faecal calprotectin and histologic remission in ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 689-698	6.1	29
451	Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2526-2534.e9	6.9	18
450	Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?. *Expert Opinion on Biological Therapy*, **2020**, 20, 353-361	5.4	3
449	Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. *Techniques in Coloproctology*, **2020**, 24, 105-126	2.9	22
448	Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. *Journal of Crohn's and Colitis*, **2020**, 14, 743-756	1.5	3
447	Positioning Therapies in Ulcerative Colitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1280-1290.e1	6.9	30
446	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. *Drugs*, **2020**, 80, 99-113	12.1	32
445	Efficacy of anti-TNF drugs in patients with stricturing Crohn's disease. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 347-353	4.2	4
444	Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1663-1672	6.9	285
443	Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor. *EBioMedicine*, **2020**, 54, 102719	8.8	29
442	Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 1087-1095	6.1	8
441	Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 598-606	18.8	63
440	Gastroenterology department operational reorganisation at the time of covid-19 outbreak: an Italian and Chinese experience. *Gut*, **2020**, 69, 981-983	19.2	26
439	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. *Inflammatory Bowel Diseases*, **2020**, 26, 304-313	4.5	6
438	Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 1658-1675	6.1	15
437	S0653 Long-Term Treatment With Vedolizumab SC in Ulcerative Colitis: Interim Results From VISIBLE OLE. *American Journal of Gastroenterology*, **2020**, 115, S327-S327	0.7	1
436	Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. *British Medical Bulletin*, **2020**, 136, 107-117	5.4	1
435	Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. *Journal of Clinical Medicine*, **2020**, 9,	5.1	5

434	Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. *Journal of Clinical Medicine*, **2020**, 9,	5.1	86
433	Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 765-773	4.2	3
432	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2366-2368.e3	6.9	35
431	Protecting patients with IBD during the COVID-19 pandemic. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 639	18.8	1
430	Is It Crohn's Disease?. *Gastroenterology*, **2020**, 159, 1244-1246	13.3	2
429	Long-term safety of approved biologics for ulcerative colitis. *Expert Opinion on Drug Safety*, **2020**, 19, 807-816	4.1	6
428	P565 Efficacy and safety of long-term treatment with ustekinumab in moderate-to-severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension. *Journal of Crohn's and Colitis*, **2020**, 14, S476-S477	1.5	2
427	Gastrointestinal involvement attenuates COVID-19 severity and mortality **2020**,		19
426	Inflammatory bowel disease: estimates from the global burden of disease 2017 study. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 261-270	6.1	21
425	Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 271-280	6.1	27
424	Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. *Gastroenterology*, **2020**, 158, 1554-1573.e12	13.3	84
423	Treatment of Perianal Fistulas in Crohn's Disease, Seton Versus Anti-TNF Versus Surgical Closure Following Anti-TNF [PISA]: A Randomised Controlled Trial. *Journal of Crohn's and Colitis*, **2020**, 14, 1049-1056	1.5	22
422	Is there a role for therapeutic sphingolipids in inflammatory bowel disease?. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 47-54	4.2	4
421	Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. *Journal of Crohn's and Colitis*, **2020**, 14, 688-693	1.5	8
420	Histological healing: should it be considered as a new outcome for ulcerative colitis?. *Expert Opinion on Biological Therapy*, **2020**, 20, 407-412	5.4	8
419	Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. *Journal of Crohn's and Colitis*, **2020**, 14, 710-718	1.5	1
418	Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure. *American Journal of Gastroenterology*, **2020**, 115, 179-189	0.7	23
417	Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1309-1323.e4	6.9	17

416	Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2244-2255.e9	6.9	30
415	Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. *Expert Opinion on Biological Therapy*, **2020**, 20, 151-161	5.4	2
414	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. *Digestive and Liver Disease*, **2020**, 52, 138-142	3.3	13
413	Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. *Digestive and Liver Disease*, **2020**, 52, 506-515	3.3	9
412	Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide. *Clinical Gastroenterology and Hepatology*, **2020**,	6.9	6
411	Reply. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 3055	6.9	1
410	Predictors for short bowel syndrome in Crohn's disease. *Digestive and Liver Disease*, **2020**, 52, 1455-1460	3.3	1
409	Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. *Nature Reviews Rheumatology*, **2020**, 16, 415-433	8.1	38
408	Ustekinumab for treating ulcerative colitis: an expert opinion. *Expert Opinion on Biological Therapy*, **2020**, 20, 1321-1329	5.4	2
407	Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
406	New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?. *Current Opinion in Pharmacology*, **2020**, 55, 141-150	5.1	6
405	Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy. *Annals of Internal Medicine*, **2020**, 173, 405-407	8	15
404	Reply. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 3057-3058	6.9	2
403	Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 829-841	4.2	1
402	Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?. *Expert Review of Gastroenterology and Hepatology*, **2020**, 14, 807-817	4.2	5
401	Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2689-2700	6.9	38
400	Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review. *United European Gastroenterology Journal*, **2020**, 8, 886-922	5.3	2
399	Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. *Journal of Crohn's and Colitis*, **2020**, 14, S798-S806	1.5	51

398	The Role of Pro-Resolving Lipid Mediators in Colorectal Cancer-Associated Inflammation: Implications for Therapeutic Strategies. *Cancers*, **2020**, 12,	6.6	5
397	Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials. *United European Gastroenterology Journal*, **2020**, 8, 1013-1030	5.3	5
396	Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. *American Journal of Gastroenterology*, **2020**, 115, 1719-1721	0.7	2
395	Long-term safety of vedolizumab for inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 1353-1365	6.1	34
394	Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. *Expert Review of Clinical Immunology*, **2020**, 16, 1019-1028	5.1	5
393	Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
392	Ulcerative colitis. *Nature Reviews Disease Primers*, **2020**, 6, 74	51.1	182
391	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
390	Early Intervention in Ulcerative Colitis: Ready for Prime Time?. *Journal of Clinical Medicine*, **2020**, 9,	5.1	12
389	The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. *Medicinal Research Reviews*, **2020**, 40, 245-262	14.4	28
388	Evolving therapeutic goals in ulcerative colitis: towards disease clearance. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 1-2	24.2	42
387	Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. *Gastroenterology*, **2020**, 158, 562-572.e12	13.3	65
386	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 14-23	6.9	38
385	Application of Artificial Intelligence to Gastroenterology and Hepatology. *Gastroenterology*, **2020**, 158, 76-94.e2	13.3	162
384	Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. *Expert Opinion on Biological Therapy*, **2020**, 20, 363-378	5.4	22
383	Environmental, Nutritional, and Socioeconomic Determinants of IBD Incidence: A Global Ecological Study. *Journal of Crohn's and Colitis*, **2020**, 14, 323-331	1.5	5
382	Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1882-1883	6.9	30
381	Head-to-head trials in inflammatory bowel disease: past, present and future. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 365-376	24.2	20

380	Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. *Gastroenterology*, **2020**, 158, 2302-2304	13.3	27
379	OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study. *Journal of Crohn's and Colitis*, **2020**, 14, S020-S021	1.5	7
378	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. *Angiology*, **2020**, 71, 689-697	2.1	11
377	Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2020**,	1.5	15
376	The gut virome in inflammatory bowel disease pathogenesis: From metagenomics to novel therapeutic approaches. *United European Gastroenterology Journal*, **2019**, 7, 999-1007	5.3	17
375	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. *Gastroenterology Research and Practice*, **2019**, 2019, 3108025	2	4
374	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. *Gastroenterology*, **2019**, 157, 1007-1018.e7	13.3	82
373	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. *Gastroenterology*, **2019**, 157, 1032-1043.e1	13.3	31
372	Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. *Current Pharmaceutical Design*, **2019**, 25, 25-31	3.3	5
371	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. *New England Journal of Medicine*, **2019**, 381, 1215-1226	59.2	240
370	Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. *New England Journal of Medicine*, **2019**, 381, 1201-1214	59.2	354
369	OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn's disease: final results from the GEMINI LTS study. *Journal of Crohn's and Colitis*, **2019**, 13, S018-S020	1.5	6
368	OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM. *Journal of Crohn's and Colitis*, **2019**, 13, S024-S025	1.5	12
367	OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI. *Journal of Crohn's and Colitis*, **2019**, 13, S025-S026	1.5	12
366	DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study. *Journal of Crohn's and Colitis*, **2019**, 13, S054-S055	1.5	1
365	DOP48 Amiselimod, a selective S1P receptor modulator in Crohn's disease patients: a proof-of-concept study. *Journal of Crohn's and Colitis*, **2019**, 13, S055-S056	1.5	9
364	DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II. *Journal of Crohn's and Colitis*, **2019**, 13, S056-S057	1.5	4
363	DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn's disease: data from the CELEST study. *Journal of Crohn's and Colitis*, **2019**, 13, S057-S057	1.5	2

362	DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis. *Journal of Crohn's and Colitis*, **2019**, 13, S058-S059	1.5	2
361	DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial. *Journal of Crohn's and Colitis*, **2019**, 13, S061-S062	1.5	4
360	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. *Inflammatory Bowel Diseases*, **2019**, 25, 1399-1407	4.5	11
359	Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2019**, 13, 970-975	1.5	26
358	JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?. *Gut*, **2019**, 68, 1893-1899	19.2	55
357	Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. *Cancer Research*, **2019**, 79, 4196-4210	10.1	34
356	P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI. *Journal of Crohn's and Colitis*, **2019**, 13, S256-S257	1.5	1
355	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. *Cells*, **2019**, 8,	7.9	7
354	Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. *Therapeutic Advances in Gastroenterology*, **2019**, 12, 1756284819848631	4.7	33
353	Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. *Gastroenterology*, **2019**, 156, 2349-2351	13.3	1
352	Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. *Journal of Crohn's and Colitis*, **2019**, 13, 1569-1577	1.5	19
351	Detection and management of early stage inflammatory bowel disease: an update for clinicians. *Expert Review of Gastroenterology and Hepatology*, **2019**, 13, 547-555	4.2	4
350	P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study. *Journal of Crohn's and Colitis*, **2019**, 13, S350-S351	1.5	
349	Psychological Functioning of Patients With Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2019**, 25, e112	4.5	0
348	Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. *Immunotherapy*, **2019**, 11, 565-575	3.8	2
347	Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11. *International Journal of Cancer*, **2019**, 145, 1913-1920	7.5	11
346	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Digestive and Liver Disease*, **2019**, 51, 632-639	3.3	22
345	P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies. *Journal of Crohn's and Colitis*, **2019**, 13, S460-S460	1.5	1

344	P029 Serum bile acids profiling in IBD patients treated with anti-TNFs. *Journal of Crohn's and Colitis*, **2019**, 13, S100-S101	1.5	
343	OP33 BUB1: a new player in the development of Crohn's disease (CD)-associated fibrosis. *Journal of Crohn's and Colitis*, **2019**, 13, S612-S612	1.5	1
342	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 1181-1187	6.1	31
341	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. *Digestive Diseases*, **2019**, 37, 266-283	3.2	29
340	P499 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn's disease: results from VISIBLE 1 and 2. *Journal of Crohn's and Colitis*, **2019**, 13, S361-S362	1.5	
339	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. *Inflammatory Bowel Diseases*, **2019**, 25, 568-579	4.5	35
338	Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs. *Cells*, **2019**, 8,	7.9	5
337	Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences. *United European Gastroenterology Journal*, **2019**, 7, 1008-1032	5.3	32
336	Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. *Expert Review of Gastroenterology and Hepatology*, **2019**, 13, 731-738	4.2	10
335	Safety of vedolizumab in liver transplant recipients: A systematic review. *United European Gastroenterology Journal*, **2019**, 7, 875-880	5.3	2
334	mTOR-Dependent Stimulation of Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease. *Cells*, **2019**, 8,	7.9	6
333	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®) for active, mild-to-moderate ulcerative colitis. *United European Gastroenterology Journal*, **2019**, 7, 1171-1182	5.3	5
332	Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. *Gastroenterology*, **2019**, 157, 647-659.e4	13.3	155
331	Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. *British Journal of Clinical Pharmacology*, **2019**, 85, 2244-2254	3.8	5
330	Comorbidities in inflammatory bowel disease: a call for action. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 643-654	18.8	43
329	Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2397-2415	6.9	22
328	Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. *Gastroenterology*, **2019**,	13.3	17
327	P258 Abdominal pain and its relationship with clinical outcomes, biomarker levels, and health-related quality of life in patients with moderate to severe ulcerative colitis: data from U-ACHIEVE, a Phase 2b study of upadacitinib. *Journal of Crohn's and Colitis*, **2019**, 13, S226-S226	1.5	1

326	P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies. *Journal of Crohn's and Colitis*, **2019**, 13, S311-S312	1.5	
325	P311 Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study. *Journal of Crohn's and Colitis*, **2019**, 13, S255-S256	1.5	1
324	Improving the quality of surveillance colonoscopy in inflammatory bowel disease. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 971-983	18.8	13
323	Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. *Alimentary Pharmacology and Therapeutics*, **2019**, 50, 1068-1076	6.1	92
322	NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer. *JCI Insight*, **2019**, 4,	9.9	33
321	Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease. *Drugs of Today* , **2019**, 55, 95-105	2.5	12
320	832 Pharmacokinetics and Exposure-Response Relationships of Ustekinumab in Patients With Ulcerative Colitis: Results From the UNIFI Induction and Maintenance Studies. *American Journal of Gastroenterology*, **2019**, 114, S481-S482	0.7	2
319	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. *Current Medicinal Chemistry*, **2019**, 26, 259-269	4.3	25
318	Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. *Current Medicinal Chemistry*, **2019**, 26, 280-287	4.3	5
317	Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?. *Current Pharmaceutical Design*, **2019**, 25, 19-24	3.3	1
316	Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?. *Current Pharmaceutical Design*, **2019** , 25, 47-56	3.3	2
315	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. *Current Pharmaceutical Design*, **2019**, 25, 7-12	3.3	6
314	Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile. *Current Drug Targets*, **2019**, 20, 1327-1338	3	1
313	Anti-TNF and Postoperative Complications in Abdominal Crohn's Disease Surgery. *Current Drug Targets*, **2019**, 20, 1339-1348	3	7
312	Are Surgical Rates Decreasing in the Biological Era In IBD?. *Current Drug Targets*, **2019**, 20, 1356-1362	3	10
311	817 Identification of Biomarkers and Mechanistic Insight for Upadacitinib in Crohn's Disease: Serum Inflammatory Mediator Analysis From the Phase 2b CELEST Study. *American Journal of Gastroenterology*, **2019**, 114, S471-S471	0.7	
310	Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study. *Journal of Gastrointestinal and Liver Diseases*, **2019**, 28, 49-52	1.4	0
309	Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI **2019**, 57,		2

308	OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. *Journal of Crohn's and Colitis*, **2019**, 13, S612-S613	1.5	19
307	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. *Scientific Reports*, **2019**, 9, 2064	4.9	32
306	P376 Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn's disease: results from the Phase 3b VERSIFY trial. *Journal of Crohn's and Colitis*, **2019**, 13, S293-S294	1.5	1
305	715 Corticosteroid Sparing Effects of Ustekinumab Therapy in UC Patients: Results From the UNIFI Program. *American Journal of Gastroenterology*, **2019**, 114, S421-S421	0.7	
304	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. *European Journal of Gastroenterology and Hepatology*, **2019**, 31, 1361-1369	2.2	7
303	689 Early Improvement After Intravenous Ustekinumab Induction in Patients With Ulcerative Colitis: Results From the UNIFI Induction Trial. *American Journal of Gastroenterology*, **2019**, 114, S404-S404	0.7	
302	842 Impact of Response and Inflammatory Burden at Start of Maintenance Therapy on Clinical Efficacy of Ustekinumab Dosing Regimen in UC: Week 44 Results From UNIFI. *American Journal of Gastroenterology*, **2019**, 114, S487-S488	0.7	
301	757 Histologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY. *American Journal of Gastroenterology*, **2019**, 114, S442-S442	0.7	
300	697 Safety of Ustekinumab in Inflammatory Bowel Diseases: Integrated Safety Analysis of Results From Phase 2 and 3 Studies in Crohn's Disease and Ulcerative Colitis. *American Journal of Gastroenterology*, **2019**, 114, S408-S409	0.7	
299	Time to include patients with ulcerative proctitis in clinical trials. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 900-902	18.8	2
298	Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. *United European Gastroenterology Journal*, **2019**, 7, 1285-1303	5.3	14
297	Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey. *United European Gastroenterology Journal*, **2019**, 7, 1345-1352	5.3	15
296	634 Transitioning From Vedolizumab IV to Vedolizumab SC in Patients With Ulcerative Colitis: Results From the VISIBLE Program. *American Journal of Gastroenterology*, **2019**, 114, S369-S370	0.7	1
295	P380 A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis. *Journal of Crohn's and Colitis*, **2019**, 13, S296-S297	1.5	
294	215 Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE. *American Journal of Gastroenterology*, **2019**, 114, S131-S131	0.7	1
293	772 Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT II. *American Journal of Gastroenterology*, **2019**, 114, S448-S449	0.7	1
292	644 Incidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program. *American Journal of Gastroenterology*, **2019**, 114, S377-S377	0.7	
291	P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II). *Inflammatory Bowel Diseases*, **2019**, 25, S18-S18	4.5	3

290	Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 838-846.e2	6.9	62
289	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 139-147	6.9	78
288	Treatments for Crohn's Disease-Associated Bowel Damage: A Systematic Review. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 847-856	6.9	17
287	Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. *Digestive and Liver Disease*, **2019**, 51, 327-334	3.3	14
286	Biosimilars of adalimumab: the upcoming challenge in IBD. *Expert Opinion on Biological Therapy*, **2019**, 19, 1023-1030	5.4	13
285	Big data in IBD: a look into the future. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 312-321	24.2	58
284	Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. *Inflammatory Bowel Diseases*, **2019**, 25, 945-954	4.5	11
283	Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. *Journal of Crohn's and Colitis*, **2019**, 13, 417-423	1.5	22
282	Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2019**, 13, 659-668	1.5	32
281	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 1673-1679.e1	6.9	13
280	Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. *Inflammatory Bowel Diseases*, **2019**, 25, 803-810	4.5	17
279	Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. *Gut Microbes*, **2019**, 10, 149-158	8.8	36
278	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). *Gut*, **2019**, 68, 40-48	19.2	75
277	Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2018**, 24, 601-606	4.5	42
276	Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. *Journal of Crohn's and Colitis*, **2018**, 12, 621-626	1.5	47
275	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. *Journal of Crohn's and Colitis*, **2018**, 12, 687-694	1.5	7
274	Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. *Drugs*, **2018**, 78, 463-478	12.1	123
273	Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. *Inflammatory Bowel Diseases*, **2018**, 24, 2106-2112	4.5	11

272	Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!. *Gastroenterology*, **2018**, 154, 1196-1198	13.3	2
271	Vedolizumab for the treatment of Crohn's disease. *Expert Review of Clinical Immunology*, **2018**, 14, 179-189	3.2	6
270	Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. *European Journal of Gastroenterology and Hepatology*, **2018**, 30, 316-322	2.2	20
269	Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 773-783	6.1	4
268	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. *Gastroenterology*, **2018**, 154, 1334-1342.e4	13.3	220
267	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. *Gastroenterology*, **2018**, 154, 1320-1333.e10	13.3	82
266	Diffusion-weighted MRI in inflammatory bowel disease. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 433-443	18.8	13
265	Infliximab biosimilar CT-P13 for inflammatory bowel disease. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 373-375	18.8	5
264	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. *Gastroenterology*, **2018**, 155, 76-87	13.3	29
263	Ustekinumab in the management of Crohn's disease: Expert opinion. *Digestive and Liver Disease*, **2018**, 50, 653-660	3.3	14
262	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. *United European Gastroenterology Journal*, **2018**, 6, 310-321	5.3	18
261	Development of an index to define overall disease severity in IBD. *Gut*, **2018**, 67, 244-254	19.2	73
260	Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. *Gut*, **2018**, 67, 53-60	19.2	126
259	Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. *Journal of Crohn's and Colitis*, **2018**, 12, S678-S686	1.5	33
258	TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice. *Journal of Crohn's and Colitis*, **2018**, 12, 230-244	1.5	32
257	Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. *British Journal of Clinical Pharmacology*, **2018**, 84, 239-251	3.8	24
256	Unmet Needs in IBD: the Case of Fatigue. *Clinical Reviews in Allergy and Immunology*, **2018**, 55, 368-378	12.3	15
255	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. *Journal of Crohn's and Colitis*, **2018**, 12, 105-119	1.5	55

254	Can IL-23 be a good target for ulcerative colitis?. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2018**, 32-33, 95-102	2.5	23
253	Review article: treating-to-target for inflammatory bowel disease-associated anaemia. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 610-617	6.1	19
252	Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. *Journal of Crohns and Colitis*, **2018**, 12, 1180-1190	1.5	16
251	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. *Journal of Crohns and Colitis*, **2018**, 12, 1280-1287	1.5	39
250	PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. *Expert Opinion on Investigational Drugs*, **2018**, 27, 623-629	5.9	3
249	Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2018**, 32-33, 17-25	2.5	7
248	The nocebo effect: a clinical challenge in the era of biosimilars. *Expert Review of Clinical Immunology* , **2018**, 14, 739-749	5.1	49
247	Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?. *Current Drug Targets*, **2018**, 19, 748-756	3	2
246	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. *Journal of Crohns and Colitis*, **2018**, 12, 1385-1391	1.5	40
245	Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2018**, 32-33, 43-47	2.5	20
244	Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 507-522	6.1	16
243	The impact of biologics in surgical outcomes in ulcerative colitis. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2018**, 32-33, 79-87	2.5	15
242	IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. *Nature Communications*, **2018**, 9, 2427	17.4	95
241	Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 454-465	6.1	87
240	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. *Intestinal Research*, **2018**, 16, 522-528	4.1	11
239	Evolving Treatment Algorithms in Crohn's Disease. *Current Drug Targets*, **2018**, 19, 782-790	3	2
238	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 941-950	6.1	17
237	Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. *Journal of Crohns and Colitis*, **2018**, 12, 1021-1029	1.5	15

236	Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes". *Drugs*, **2018**, 78, 853-855	12.1	1
235	JAK inhibitors: Novel developments in management of ulcerative colitis. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2018**, 32-33, 89-93	2.5	15
234	Colorectal cancer prevention in patients with ulcerative colitis. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2018**, 32-33, 103-109	2.5	35
233	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. *Digestive Diseases*, **2018**, 36, 346-353	3.2	3
232	Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations. *Journal of Crohns and Colitis*, **2018**, 12, 1257-1258	1.5	1
231	Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. *Expert Opinion on Investigational Drugs*, **2018**, 27, 595-599	5.9	46
230	Development and validation of the Nancy histological index for UC. *Gut*, **2017**, 66, 43-49	19.2	196
229	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Digestive and Liver Disease*, **2017**, 49, 338-358	3.3	34
228	Disease-related and drug-induced skin manifestations in inflammatory bowel disease. *Expert Review of Gastroenterology and Hepatology*, **2017**, 11, 203-214	4.2	14
227	IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy. *Expert Review of Clinical Immunology*, **2017**, 13, 457-467	5.1	12
226	Next generation of small molecules in inflammatory bowel disease. *Gut*, **2017**, 66, 199-209	19.2	78
225	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. *Digestive and Liver Disease*, **2017**, 49, 604-617	3.3	34
224	The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut*, **2017**, 66, 839-851	19.2	478
223	Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 1179-1192	6.1	54
222	The safety of biological pharmacotherapy for the treatment of ulcerative colitis. *Expert Opinion on Drug Safety*, **2017**, 16, 437-443	4.1	22
221	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 1058-1072	6.1	35
220	JAK inhibition in inflammatory bowel disease. *Expert Review of Clinical Immunology*, **2017**, 13, 693-703	5.1	55
219	Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. *BioDrugs*, **2017**, 31, 223-237	7.9	27

218	Efficacy and Safety of Oral Tofacitinib as Maintenance Therapy in Patients with Moderate to Severe Ulcerative Colitis: Results from a Phase 3 Randomized Controlled Trial. *Gastroenterology*, **2017**, 152, S199	13.3	2
217	Is Mesalamine Effective for the Induction of Remission in Crohn's Disease?. *Inflammatory Bowel Diseases*, **2017**, 23, E22-E23	4.5	2
216	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *New England Journal of Medicine*, **2017**, 376, 1723-1736	59.2	771
215	Surgical rates in the era of biological therapy: up, down or unchanged?. *Current Opinion in Gastroenterology*, **2017**, 33, 246-253	3	45
214	The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. *Inflammatory Bowel Diseases*, **2017**, 23, 233-243	4.5	96
213	Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2017**, 390, 135-144	40	119
212	Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. *Journal of Crohn's and Colitis*, **2017**, 11, 1258-1266	1.5	13
211	Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm. *Gastroenterology*, **2017**, 152, S155	13.3	12
210	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. *Journal of Autoimmunity*, **2017**, 80, 10-27	15.5	78
209	Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. *Journal of Crohn's and Colitis*, **2017**, 11, 921-929	1.5	99
208	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. *Gastroenterology*, **2017**, 153, 77-86.e6	13.3	162
207	Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. *Inflammatory Bowel Diseases*, **2017**, 23, 976-985	4.5	24
206	Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. *Digestive and Liver Disease*, **2017**, 49, 872-877	3.3	22
205	ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. *Journal of Crohn's and Colitis*, **2017**, 11, 26-34	1.5	148
204	Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis. *Journal of Pathology*, **2017**, 241, 547-558	9.4	21
203	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. *Lancet, The*, **2017**, 390, 2779-2789	40	403
202	Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. *Journal of Crohn's and Colitis*, **2017**, 11, 274-280	1.5	29
201	Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. *Journal of Digestive Diseases*, **2017**, 18, 566-573	3.3	8

200	E-health in inflammatory bowel diseases: More challenges than opportunities?. *Digestive and Liver Disease*, **2017**, 49, 1320-1326	3.3	16
199	Management of patients with inflammatory bowel disease and spondyloarthritis. *Expert Review of Clinical Pharmacology*, **2017**, 10, 1363-1374	3.8	11
198	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. *Digestion*, **2017**, 96, 166-172	3.6	11
197	Early intervention in Crohn's disease: towards disease modification trials. *Gut*, **2017**, 66, 2179-2187	19.2	60
196	Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. *Journal of Crohn's and Colitis*, **2017**, 11, 1317-1325	1.5	26
195	Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. *Digestive and Liver Disease*, **2017**, 49, 864-871	3.3	2
194	A Prolonged Follow-Up on the Efficacy and Safety of Infliximab Biosimilar CT-P13 in IBD Across Italy: The Prosit Cohort. *Gastroenterology*, **2017**, 152, S108	13.3	2
193	Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. *Clinical Pharmacology and Therapeutics*, **2017**, 102, 633-641	6.1	25
192	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. *Gastroenterology*, **2017**, 152, S602	13.3	7
191	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. *Gastroenterology*, **2017**, 153, 1363-1377.e6	13.3	34
190	Preventing disability in inflammatory bowel disease. *Therapeutic Advances in Gastroenterology*, **2017**, 10, 865-876	4.7	18
189	Filgotinib in Crohn's Disease: JAK Is Back. *Gastroenterology*, **2017**, 153, 603-605	13.3	12
188	Novel therapeutic targets for inflammatory bowel disease. *Journal of Autoimmunity*, **2017**, 85, 103-116	15.5	66
187	IBD: To switch or not to switch: that is the biosimilar question. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 508-509	24.2	8
186	Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. *Journal of Crohn's and Colitis*, **2017**, 11, 128-133	1.5	64
185	Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 125-135	2.4	87
184	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. *Journal of Crohn's and Colitis*, **2017**, 11, 135-149	1.5	387
183	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 229-239.e5	6.9	112

182	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". *Digestive and Liver Disease*, **2017**, 49, 17-23	3.3	26
181	Biosimilars in IBD: from theory to practice. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 22-31	24.2	66
180	Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. *Clinical and Translational Gastroenterology*, **2017**, 8, e126	4.2	6
179	Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 903-905	6.1	7
178	P004 Stimulation of CYP450-mediated □3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel disease. *Journal of Crohn's and Colitis*, **2017**, 11, S81-S81	1.5	
177	PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	27
176	Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases. *Frontiers in Immunology*, **2017**, 8, 1331	8.4	38
175	Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohn□ Disease. *American Journal of Gastroenterology*, **2017**, 112, S371	0.7	4
174	The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. *Current Pharmaceutical Design*, **2017**, 23, 6759-6769	3.3	7
173	Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. *Minerva Gastroenterology*, **2017**, 63, 319-326	3	1
172	A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn□ Disease: Data From CALM 2017 ACG Governors Award for Excellence in Clinical Research. *American Journal of Gastroenterology*, **2017**, 112, S321	0.7	0
171	Symptomatic Improvement Within 3 Days With Tofacitinib Induction Therapy in Patients With Ulcerative Colitis: Results From OCTAVE Induction 1 and 2. *American Journal of Gastroenterology*, **2017**, 112, S331	0.7	
170	Long-term Efficacy of Vedolizumab for Crohn's Disease. *Journal of Crohn's and Colitis*, **2017**, 11, 412-424	1.5	112
169	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. *Journal of Crohn's and Colitis*, **2017**, 11, 400-411	1.5	109
168	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 348-354.e17	6.9	217
167	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. *Lancet, The*, **2016**, 388, 1281-90	40	539
166	Are We Ready to Abandon Placebo in Randomised Clinical Trials for Inflammatory Bowel Disease? Pros and Cons. *Journal of Crohn's and Colitis*, **2016**, 10 Suppl 2, S548-52	1.5	4
165	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. *BMJ Open Gastroenterology*, **2016**, 3, e000092	3.9	7

164	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1426-1432.e1	6.9	28
163	764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders. *Gastroenterology*, **2016**, 150, S155	13.3	6
162	The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. *Therapeutic Advances in Gastroenterology*, **2016**, 9, 503-12	4.7	15
161	Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. *United European Gastroenterology Journal*, **2016**, 4, 784-793	5.3	52
160	Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. *United European Gastroenterology Journal*, **2016**, 4, 604-13	5.3	24
159	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. *Digestive and Liver Disease*, **2016**, 48, 360-70	3.3	29
158	Preventing Collateral Damage in Crohn's Disease: The L[illegible]hann Index. *Journal of Crohn's and Colitis*, **2016**, 10, 495-500	1.5	15
157	Perception of Reproductive Health in Women with Inflammatory Bowel Disease. *Journal of Crohn's and Colitis*, **2016**, 10, 886-91	1.5	32
156	Emerging therapeutic targets and strategies in Crohn's disease. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 735-44	4.2	5
155	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. *Gastroenterology*, **2016**, 150, 380-8.e4	13.3	85
154	JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. *American Journal of Physiology - Renal Physiology*, **2016**, 310, G155-62	5.1	100
153	The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 638-9	6.9	1
152	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. *Gastroenterology*, **2016**, 150, 1568-1578	13.3	171
151	Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge. *Journal of Crohn's and Colitis*, **2016**, 10, 1096-102	1.5	22
150	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. *Gut*, **2016**, 65, 1447-55	19.2	102
149	Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. *Journal of Clinical Investigation*, **2016**, 126, 611-26	15.9	26
148	Onset of Efficacy of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Multinational, Phase 3 Clinical Trials. *American Journal of Gastroenterology*, **2016**, 111, S260-S261	0.7	2
147	Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. *World Journal of Gastroenterology*, **2016**, 22, 4594-603	5.6	29

146	Drug development in IBD: from novel target identification to early clinical trials. *Gut*, **2016**, 65, 1233-9	19.2	27
145	PTU-072 Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study. *Gut*, **2016**, 65, A88-A89	19.2	
144	Indirect Treatment Comparison of Ustekinumab Versus Other Biologics In Moderate To Severe Crohn's Disease: A 1-Year Treatment Sequence Analysis. *Value in Health*, **2016**, 19, A576	3.3	6
143	Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization. *Inflammatory Bowel Diseases*, **2016**, 22, 2390-401	4.5	10
142	439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars. *Gastroenterology*, **2016**, 150, S92	13.3	5
141	Programming of Intestinal Epithelial Differentiation by IL-33 Derived from Pericryptal Fibroblasts in Response to Systemic Infection. *Cell Reports*, **2016**, 15, 1743-56	10.6	66
140	Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Medicine (United States)*, **2016**, 95, e2308	1.8	51
139	Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. *Journal of Crohn's and Colitis*, **2016**, 10, 1362-1365	1.5	67
138	Endothelial Cell-Immune Cell Interaction in IBD. *Digestive Diseases*, **2016**, 34, 43-50	3.2	14
137	Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1385-1397.e10	6.9	219
136	Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. *Gut*, **2015**, 64, 243-9	19.2	113
135	Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. *Immunotherapy*, **2015**, 7, 175-90	3.8	12
134	Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9´mg: pooled analysis of two phase 3 studies. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 409-18	6.1	52
133	European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. *Journal of Crohn's and Colitis*, **2015**, 9, 211-22	1.5	278
132	Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database. *Journal of Crohn's and Colitis*, **2015**, 9, 541-7	1.5	19
131	In the Presence of Conceptual Heterogeneity, Results of Network Meta-analysis Comparing Therapies in Crohn's Disease Need to Be Interpreted With Caution. *Gastroenterology*, **2015**, 148, 1483-4	13.3	8
130	New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. *Scandinavian Journal of Gastroenterology*, **2015**, 50, 113-20	2.4	10
129	Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion. *Gastroenterology*, **2015**, 148, 1438-51.e8	13.3	76

128	Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine. *Gastroenterology*, **2015**, 149, 163-176.e20	13.3	142
127	Biosimilars - terms of use. *Current Medical Research and Opinion*, **2015**, 31, 2325-30	2.5	12
126	Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1. *Cancer Research*, **2015**, 75, 4895-909	10.1	8
125	Biologic agents for IBD: practical insights. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 537-45	24.2	196
124	Adalimumab for the treatment of pediatric Crohn's disease. *Expert Review of Clinical Immunology*, **2015**, 11, 963-72	5.1	3
123	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *American Journal of Gastroenterology*, **2015**, 110, 1324-38	0.7	1024
122	Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. *Journal of Crohn's and Colitis*, **2015**, 9, 633-9	1.5	52
121	Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. *Journal of Crohn's and Colitis*, **2015**, 9, 738-46	1.5	23
120	Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?. *Gastroenterology*, **2015**, 149, 1121-3	13.3	4
119	Comparing histological activity indexes in UC. *Gut*, **2015**, 64, 1412-8	19.2	103
118	Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. *Gastroenterology*, **2015**, 148, 52-63.e3	13.3	198
117	Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. *Inflammatory Bowel Diseases*, **2015**, 21, 1204-13	4.5	19
116	Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 664-84	6.1	77
115	Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. *Scientific Reports*, **2015**, 5, 13647	4.9	25
114	Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. *Trials*, **2015**, 16, 366	2.8	33
113	Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology. *Journal of Translational Medicine*, **2015**, 13, 322	8.5	2
112	Review article: the histological assessment of disease activity in ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 957-67	6.1	41
111	Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 1055-65	6.1	49

110	Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. *European Journal of Clinical Pharmacology*, **2015**, 71, 773-99	2.8	11
109	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. *Journal of Crohn's and Colitis*, **2015**, 9, 601-6	1.5	47
108	The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation. *Gut*, **2015**, 64, 589-600	19.2	24
107	Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2015**, 314, 2524-34	27.4	102
106	Integrins and adhesion molecules as targets to treat inflammatory bowel disease. *Current Opinion in Pharmacology*, **2015**, 25, 67-71	5.1	20
105	Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is the crystal ball?. *Gut*, **2015**, 64, 1347-8	19.2	2
104	Golimumab: clinical update on its use for ulcerative colitis. *Drugs of Today*, **2015**, 51, 171-84	2.5	3
103	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. *Autoimmunity Reviews*, **2014**, 13, 751-5	13.6	59
102	Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. *Digestive and Liver Disease*, **2014**, 46, 330-4	3.3	10
101	Management of gastrointestinal and liver diseases during pregnancy. *Gut*, **2014**, 63, 1014-23	19.2	25
100	Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 1095-103	6.1	45
99	Commentary: anaemia in inflammatory bowel disease--the most common and ignored extra intestinal manifestation. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 227-8	6.1	5
98	Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. *Journal of Crohn's and Colitis*, **2014**, 8, 1548-50	1.5	76
97	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. *Digestive and Liver Disease*, **2014**, 46, 963-8	3.3	36
96	Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine?. *Expert Review of Gastroenterology and Hepatology*, **2014**, 8, 835-46	4.2	24
95	Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. *Gastroenterology*, **2014**, 147, 981-9	13.3	75
94	DOP078 Are IBD specialists aware of biosimilar monoclonal antibodies? Results from a survey among ECCO members. *Journal of Crohn's and Colitis*, **2014**, 8, S53	1.5	3
93	Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). *Journal of Crohn's and Colitis*, **2014**, 8, 5-18	1.5	89

92	Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. *Gastroenterology*, **2014**, 146, 392-400.e3	13.3	593
91	Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. *Digestive and Liver Disease*, **2014**, 46, 135-9	3.3	29
90	EMA response to ECCO position statement on biosimilars. *Journal of Crohn's and Colitis*, **2014**, 8, 259	1.5	7
89	P511 Does the location of an IBD centre impact the rates of early postoperative endoscopic recurrence after ileocecal resection in Crohn's disease? Results from the MULTIPER database. *Journal of Crohn's and Colitis*, **2014**, 8, S281	1.5	2
88	Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. *Annals of Internal Medicine*, **2014**, 160, 704-11	8	158
87	Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. *Oncotarget*, **2014**, 5, 3711-27	3.3	32
86	Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E4658-67	11.5	52
85	Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis?. *Gut*, **2014**, 63, 1204-5	19.2	20
84	Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. *Expert Review of Clinical Immunology*, **2014**, 10, 885-95	5.1	7
83	Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. *Gut*, **2014**, 63, 433-41	19.2	173
82	Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology?. *Gut*, **2014**, 63, 533-5	19.2	16
81	Inflammatory bowel diseases and psychological issues: A new approach for a systematic analysis of the academic debate. *Psychology, Health and Medicine*, **2014**, 19, 559-71	2.1	4
80	Review article: optimal preparation for surgery in Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 1009-22	6.1	45
79	Patient and physician views on the quality of care in inflammatory bowel disease: results from SOLUTION-1, a prospective IG-IBD study. *Journal of Crohn's and Colitis*, **2014**, 8, 1642-52	1.5	17
78	Commentary: Adjunct antibiotic combination therapy for ulcerative colitis--is it time to investigate Fusobacterium varium?. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 1333	6.1	1
77	Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 743-4	6.1	6
76	IBD in 2013: enriching the therapeutic armamentarium for IBD. *Nature Reviews Gastroenterology and Hepatology*, **2014**, 11, 84-6	24.2	5
75	The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis. *Journal of Translational Medicine*, **2014**, 12, 293	8.5	29

74	Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn's and Ulcerative Colitis Association's online survey. *European Journal of Gastroenterology and Hepatology*, **2014**, 26, 1385-91	2.2	39
73	Proximal collagenous gastroenteritides: clinical management. A systematic review. *Annals of Medicine*, **2014**, 46, 311-7	1.5	19
72	Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. *Inflammatory Bowel Diseases*, **2014**, 20, 1368-74	4.5	45
71	P303 Ulcerative colitis (UC) in the elderly Moderate at onset but then a milder course? An IG-IBD study. *Journal of Crohn's and Colitis*, **2014**, 8, S190-S191	1.5	3
70	The biosimilar road in inflammatory bowel disease: the right way?. *Baillière's Best Practice and Research in Clinical Gastroenterology*, **2014**, 28, 465-71	2.5	21
69	OP011 Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: A phase 2 randomized placebo-controlled study. *Journal of Crohn's and Colitis*, **2014**, 8, S7-S8	1.5	5
68	Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF- agents. *Autoimmunity Reviews*, **2014**, 13, 15-9	13.6	113
67	Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. *Journal of Gastrointestinal Surgery*, **2014**, 18, 83-90; discussion 90-1	3.3	23
66	VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. *Journal of Clinical Investigation*, **2014**, 124, 3863-78	15.9	144
65	Catching the therapeutic window of opportunity in early Crohn's disease. *Current Drug Targets*, **2014**, 15, 1056-63	3	38
64	Iron deficiency: the hidden miscreant in inflammatory bowel disease. *Current Drug Targets*, **2014**, 15, 1011-9	3	1
63	Microscopic features of colorectal neoplasia in inflammatory bowel diseases. *World Journal of Gastroenterology*, **2014**, 20, 3164-72	5.6	28
62	Vedolizumab Results in Durable Clinical Remission in Crohn Disease. *American Journal of Gastroenterology*, **2014**, 109, S476-S477	0.7	
61	Vedolizumab as induction and maintenance therapy for ulcerative colitis. *New England Journal of Medicine*, **2013**, 369, 699-710	59.2	1465
60	Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease. *Digestive Diseases and Sciences*, **2013**, 58, 3246-55	4	27
59	Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases. *International Journal of Colorectal Disease*, **2013**, 28, 1281-6	3	
58	Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. *Gastroenterology*, **2013**, 144, 346-356.e3	13.3	37
57	New therapeutic avenues in ulcerative colitis: thinking out of the box. *Gut*, **2013**, 62, 1642-52	19.2	48

56	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. *Journal of Crohn's and Colitis*, **2013**, 7, 1-33	1.5	361
55	Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. *Scandinavian Journal of Gastroenterology*, **2013**, 48, 552-5	2.4	20
54	The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method. *Alimentary Pharmacology and Therapeutics*, **2013**, 38, 1109-18	6.1	16
53	Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. *Gut*, **2013**, 62, 1556-65	19.2	184
52	Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. *Gastroenterology*, **2013**, 145, 978-986.e5	13.3	124
51	Adalimumab in active ulcerative colitis: a "real-life" observational study. *Digestive and Liver Disease*, **2013**, 45, 738-43	3.3	57
50	Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis. *Journal of Gastrointestinal Surgery*, **2013**, 17, 126-32; discussion p.132	3.3	46
49	Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 277-8	6.1	1
48	Reductions in Corticosteroid Use in Patients with Ulcerative Colitis or Crohn's Disease Treated with Vedolizumab. *American Journal of Gastroenterology*, **2013**, 108, S503	0.7	5
47	Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. *Journal of Crohn's and Colitis*, **2013**, 7, 556-85	1.5	438
46	Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 855-66	6.1	76
45	First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. *Nature Reviews Gastroenterology and Hepatology*, **2013**, 10, 345-51	24.2	46
44	ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). *Journal of Crohn's and Colitis*, **2013**, 7, 586-9	1.5	149
43	Adalimumab in ulcerative colitis: ready for prime time. *Digestive and Liver Disease*, **2013**, 45, 8-13	3.3	9
42	Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study. *Alimentary Pharmacology and Therapeutics*, **2013**, 38, 741-51	6.1	98
41	Mesenchymal stromal cells in inflammatory bowel disease: conspirators within the 'colitogenic niche'?. *Gut*, **2013**, 62, 1098-9	19.2	5
40	FOXP3+ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNF agents. *BioMed Research International*, **2013**, 2013, 286368	3	24
39	Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease. *Current Opinion in Gastroenterology*, **2013**, 29, 608-13	3	37

38	Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. *European Journal of Gastroenterology and Hepatology*, **2013**, 25, 1456-63	2.2	41
37	Leukoapheresis in Crohn's disease: the final curtain?. *Gut*, **2013**, 62, 487-8	19.2	0
36	Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 840-2	6.1	11
35	Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. *Clinical and Experimental Immunology*, **2013**, 173, 250-8	6.2	94
34	Commentary: antibodies reacting with the infliximab Fab portion--something new?. *Alimentary Pharmacology and Therapeutics*, **2013**, 38, 552	6.1	1
33	Cross-sectional imaging modalities in Crohn's disease. *Digestive Diseases*, **2013**, 31, 199-201	3.2	9
32	Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. *Current Drug Targets*, **2013**, 14, 1444-52	3	20
31	Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. *Inflammatory Bowel Diseases*, **2013**, 19, 1065-72	4.5	56
30	Effect of tumor necrosis factor-□blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease. *Inflammatory Bowel Diseases*, **2013**, 19, 259-64	4.5	26
29	Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn□ Disease. *American Journal of Gastroenterology*, **2013**, 108, S502-S503	0.7	12
28	Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. *Current Drug Targets*, **2013**, 14, 1433-43	3	42
27	Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. *Current Drug Targets*, **2013**, 14, 1508-21	3	45
26	New therapies for inflammatory bowel disease: from the bench to the bedside. *Gut*, **2012**, 61, 918-32	19.2	234
25	Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. *American Journal of Gastroenterology*, **2012**, 107, 1770-6	0.7	76
24	Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. *Gastroenterology*, **2012**, 143, 1461-9	13.3	39
23	Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial. *American Journal of Gastroenterology*, **2012**, 107, S609-S610	0.7	4
22	Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. *Inflammatory Bowel Diseases*, **2012**, 18, 1042-7	4.5	120
21	Integrated models of care in managing inflammatory bowel disease: a discussion. *Inflammatory Bowel Diseases*, **2012**, 18, 1582-7	4.5	42

20	Stopping infliximab in Crohn's disease: still an ongoing STORI. *Inflammatory Bowel Diseases*, **2012**, 18, 2201-2	4.5	6
19	TNF-inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease. *Gut*, **2012**, 61, 1016-27	19.2	14
18	Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. *Scandinavian Journal of Gastroenterology*, **2012**, 47, 1211-7	2.4	19
17	The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease. *Current Drug Targets*, **2012**, 13, 1273-9	3	3
16	Bowel damage assessment in Crohn's disease by magnetic resonance imaging. *Current Drug Targets* , **2012**, 13, 1300-7	3	6
15	Imaging modalities for perianal Crohn's disease. *Current Drug Targets*, **2012**, 13, 1287-93	3	11
14	Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 30-5	6.9	253
13	Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. *Journal of Crohn's and Colitis*, **2011**, 5, 477-83	1.5	247
12	Ulcerative colitis. *New England Journal of Medicine*, **2011**, 365, 1713-25	59.2	785
11	Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-therapy. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 1-10	6.1	94
10	Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut*, **2011**, 60, 463-72	19.2	426
9	Development of the Crohn's disease digestive damage score, the Lemann score. *Inflammatory Bowel Diseases*, **2011**, 17, 1415-22	4.5	395
8	MRI in Crohn's disease--current and future clinical applications. *Nature Reviews Gastroenterology and Hepatology*, **2011**, 9, 23-31	24.2	24
7	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. *Journal of Crohn's and Colitis*, **2010**, 4, 28-62	1.5	1071
6	Internet use among inflammatory bowel disease patients: an Italian multicenter survey. *European Journal of Gastroenterology and Hepatology*, **2009**, 21, 1036-41	2.2	35
5	Inflammation and coagulation in inflammatory bowel disease: The clot thickens. *American Journal of Gastroenterology*, **2007**, 102, 174-86	0.7	267
4	Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. *Gastroenterology* , **2006**, 130, 2060-73	13.3	308
3	Review article: inherited thrombophilia in inflammatory bowel disease. *American Journal of Gastroenterology*, **2003**, 98, 1247-51	0.7	75

2	Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. *American Journal of Gastroenterology*, **2001**, 96, 2677-82	0.7	75
1	High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2. *Archives of Physiology and Biochemistry*,1-8	2.2	0